Cargando…

Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

The aim of this study was to compare transarterial chemoembolization (TACE) combined with apatinib and PD-1 inhibitors (TACE-AP) with TACE combined with apatinib alone (TACE-A) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and to explore the prognostic fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Wei-Li, Zhao, Xiao-Hui, Guo, Yuan, Hu, Hong-Tao, Cao, Guang-Shao, Li, Zhen, Fan, Wei-Jun, Xu, Shi-Jun, Li, Hai-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208716/
https://www.ncbi.nlm.nih.gov/pubmed/36920551
http://dx.doi.org/10.14309/ctg.0000000000000581
_version_ 1785046729867919360
author Xia, Wei-Li
Zhao, Xiao-Hui
Guo, Yuan
Hu, Hong-Tao
Cao, Guang-Shao
Li, Zhen
Fan, Wei-Jun
Xu, Shi-Jun
Li, Hai-Liang
author_facet Xia, Wei-Li
Zhao, Xiao-Hui
Guo, Yuan
Hu, Hong-Tao
Cao, Guang-Shao
Li, Zhen
Fan, Wei-Jun
Xu, Shi-Jun
Li, Hai-Liang
author_sort Xia, Wei-Li
collection PubMed
description The aim of this study was to compare transarterial chemoembolization (TACE) combined with apatinib and PD-1 inhibitors (TACE-AP) with TACE combined with apatinib alone (TACE-A) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and to explore the prognostic factors affecting the survival of patients. METHODS: This retrospective study analyzed data of patients with HCC with PVTT who were treated with TACE-AP or TACE-A between December 2018 and June 2021. The primary end points of the study were progression-free survival (PFS) and overall survival (OS), and the secondary end points were objective response rate (ORR) and adverse events (AEs). Propensity score matching (PSM) and stabilized inverse probability weighting (sIPTW) analyses were used to reduce patient selection bias, and Cox regression analysis was used to analyze prognostic factors affecting patient survival. RESULTS: Sixty-nine and 40 patients were included in the TACE-A and TACE-AP groups, respectively. After PSM and IPTW analyses, the median PFS and median OS in the TACE-AP group were significantly higher than those in the TACE-A group (PFS: after PSM, 6.9 vs 4.0 months, P < 0.001, after IPTW, 6.5 vs 5.1 months, P < 0.001; OS: after PSM, 14.6 vs 8.5 months P < 0.001, after IPTW, 16.1 vs 10.5 months, P < 0.001). After PSM and IPTW analyses, the tumor ORR in the TACE-AP group was significantly higher than that in the TACE-A group (PSM, 53.6% vs 17.9%, P = 0.005; IPTW, 52.5% vs 28.6%, P = 0.013). All treatment-related AEs were observed to be tolerated. Multivariate Cox regression analysis showed that the main prognostic factors affecting the survival of patients were tumor number, PVTT type, alpha-fetoprotein, and treatment mode. DISCUSSION: In the treatment of patients with HCC with PVTT, TACE-AP significantly improved PFS, OS, and ORR, and the AEs were safe and controllable.
format Online
Article
Text
id pubmed-10208716
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-102087162023-05-25 Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study Xia, Wei-Li Zhao, Xiao-Hui Guo, Yuan Hu, Hong-Tao Cao, Guang-Shao Li, Zhen Fan, Wei-Jun Xu, Shi-Jun Li, Hai-Liang Clin Transl Gastroenterol Article The aim of this study was to compare transarterial chemoembolization (TACE) combined with apatinib and PD-1 inhibitors (TACE-AP) with TACE combined with apatinib alone (TACE-A) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and to explore the prognostic factors affecting the survival of patients. METHODS: This retrospective study analyzed data of patients with HCC with PVTT who were treated with TACE-AP or TACE-A between December 2018 and June 2021. The primary end points of the study were progression-free survival (PFS) and overall survival (OS), and the secondary end points were objective response rate (ORR) and adverse events (AEs). Propensity score matching (PSM) and stabilized inverse probability weighting (sIPTW) analyses were used to reduce patient selection bias, and Cox regression analysis was used to analyze prognostic factors affecting patient survival. RESULTS: Sixty-nine and 40 patients were included in the TACE-A and TACE-AP groups, respectively. After PSM and IPTW analyses, the median PFS and median OS in the TACE-AP group were significantly higher than those in the TACE-A group (PFS: after PSM, 6.9 vs 4.0 months, P < 0.001, after IPTW, 6.5 vs 5.1 months, P < 0.001; OS: after PSM, 14.6 vs 8.5 months P < 0.001, after IPTW, 16.1 vs 10.5 months, P < 0.001). After PSM and IPTW analyses, the tumor ORR in the TACE-AP group was significantly higher than that in the TACE-A group (PSM, 53.6% vs 17.9%, P = 0.005; IPTW, 52.5% vs 28.6%, P = 0.013). All treatment-related AEs were observed to be tolerated. Multivariate Cox regression analysis showed that the main prognostic factors affecting the survival of patients were tumor number, PVTT type, alpha-fetoprotein, and treatment mode. DISCUSSION: In the treatment of patients with HCC with PVTT, TACE-AP significantly improved PFS, OS, and ORR, and the AEs were safe and controllable. Wolters Kluwer 2023-03-15 /pmc/articles/PMC10208716/ /pubmed/36920551 http://dx.doi.org/10.14309/ctg.0000000000000581 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Xia, Wei-Li
Zhao, Xiao-Hui
Guo, Yuan
Hu, Hong-Tao
Cao, Guang-Shao
Li, Zhen
Fan, Wei-Jun
Xu, Shi-Jun
Li, Hai-Liang
Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
title Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
title_full Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
title_fullStr Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
title_full_unstemmed Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
title_short Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
title_sort transarterial chemoembolization combined with apatinib plus pd-1 inhibitors for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208716/
https://www.ncbi.nlm.nih.gov/pubmed/36920551
http://dx.doi.org/10.14309/ctg.0000000000000581
work_keys_str_mv AT xiaweili transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT zhaoxiaohui transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT guoyuan transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT huhongtao transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT caoguangshao transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT lizhen transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT fanweijun transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT xushijun transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy
AT lihailiang transarterialchemoembolizationcombinedwithapatinibpluspd1inhibitorsforhepatocellularcarcinomawithportalveintumorthrombusamulticenterretrospectivestudy